GPRC5D Targeted Therapies
1 drugsAbout GPRC5D
GPRC5D (G-protein coupled receptor family C group 5 member D) is a GPCR protein with expression in certain cancers, making it a potential oncology target. As a cell surface receptor, it can be targeted by antibodies and other modalities.
While there is currently no genetic evidence directly linking GPRC5D to specific diseases, the recent FDA approval of TALVEY validates GPRC5D as a therapeutic target in cancer. Modulating GPRC5D activity has demonstrated therapeutic benefits in cancer treatment.
GPRC5D is currently targeted by one FDA-approved drug, TALVEY (Johnson & Johnson), a bispecific antibody approved in 2023 for oncology indications. Johnson & Johnson is the only company with an approved drug against GPRC5D.
Top GPRC5D Drugs
Johnson & Johnson is currently the only company with an approved drug targeting GPRC5D.
The lack of competitors indicates high barriers to entry or untapped potential in the GPRC5D space.
GPRC5D Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets GPRC5D, using bispecific antibody modality.
The modality landscape suggests an opportunity for novel modalities like small molecules or ADCs.
GPRC5D Clinical Trials 35 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on GPRC5D. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 11 | 1 | 0 | 9 | 100% |
| Phase 2 | 18 | 1 | 0 | 17 | 100% |
| Phase 3 | 6 | 0 | 1 | 5 | 0% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
GPRC5D Drug Approval Timeline (2023 - 2023)
The first and most recent drug approval for GPRC5D was TALVEY in 2023.
The recent approval suggests a growing interest in GPRC5D, but saturation is low.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 23 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on GPRC5D. A trial counts if an approved drug acting on GPRC5D is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.